Business Wire (January 03, 2008)
Permanent Link:
http://vlex.com/vid/alnylam-intellectual-covering-rnai-56257992
Id. vLex: VLEX-56257992
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Alnylam Announces Continued Progress on Development of its Intellectual Property Estate Covering RNAi Therapeutics.
- Tuschl II Patent Granted in Europe and New Kreutzer-Limmer Patent Granted in Germany -
CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office has granted the previously allowed Tuschl II patent. The European patent (EP 1407044 or " '044 Patent") broadly covers compositions, methods, and uses of small interfering RNAs (siRNAs), the molecules that mediate RNAi. In addition, the company announced today that the German Patent Office has granted a new patent (DE 10066235 or " '235 patent") ...Try vLex for FREE for 3 days
Access legal information from United States including:
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here